Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin
Corresponding Author
Mark M. Rich MD, PhD
Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA
Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USASearch for more papers by this authorJames W. Teener MD
Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA
Search for more papers by this authorShawn J. Bird MD
Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA
Search for more papers by this authorCorresponding Author
Mark M. Rich MD, PhD
Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA
Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USASearch for more papers by this authorJames W. Teener MD
Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA
Search for more papers by this authorShawn J. Bird MD
Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA
Search for more papers by this author
References
- 1 Bain P, Elrington G, Goodger E, Misbah S, Panegyres P, Mac-Pherson K, Chapel H, Newsome-Davis J: A randomised double blind controlled study of intravenous immunoglobulin in the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1994; 57: 1287.
- 2 Bird SJ: Clinical and electrophysiological improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992; 42: 1422–1423.
- 3 Dau PC, Denys EH: Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. Ann Neurol 1982; 11: 570–575.
- 4 Kranz H, Caddy DJ, Williams AM, Gay W: Myasthenic syndrome: effect of choline, plasmapheresis and tests for circulating factor. J Neurol Neurosurg Psychiatry 1980; 43: 483–488.
- 5 Lang B, Johnston I, Leys K, Elrington G, Marqueze B, Leveque C, Matin-Moutot N, Seagar M, Hoshino T, Takahashi M, Sugimori M, Cherksey BD, Llinas R, Newsome-Davis J: Autoantibody specificities in Lambert-Eaton myasthenic syndrome. Ann NY Acad Sci 1993; 681: 382–393.
- 6 Newsom-Davis J, Murray NM: Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34: 480–485.
- 7
Oh SJ,
Kim DE,
Kuruoglu R,
Brooks J,
Claussen G:
Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome.
Muscle Nerve
1996;
19:
903–906.
10.1002/(SICI)1097-4598(199607)19:7<903::AID-MUS15>3.0.CO;2-J CAS PubMed Web of Science® Google Scholar
- 8 Sanders DB: Lambert-Eaton myasthenic syndrome: clinical diagnosis, immune-mediated mechanisms, and update on therapies. Ann Neurol 1995; 37(Suppl 1): S63–S73.
- 9 Sher E, Gotti C, Canal N, Scoppetta C, Piccolo G, Evoli A, Clementi F: Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet 1989; ii: 640–643.
- 10 Streib EW, Rothner AD: Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Ann Neurol 1981; 10: 448–453.
- 11 Takano H, Masami T, Koike R, Hagai H, Arakawa M, Tsuji S: Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 1994; 17: 1073–1075.
Citing Literature
